IPCALAB Intraday Analysis...

IPCALAB Share Price

Open 478.65 Change Price %
High 494.95 1 Day 13.75 2.86
Low 478.55 1 Week 12.65 2.63
Close 493.85 1 Month 20.30 4.29
Volume 142730 1 Year 12.20 2.53
52 Week High 657.60
52 Week Low 436.10
IPCALAB Important Levels
Resistance 2 509.05
Resistance 1 502.79
Pivot 489.12
Support 1 484.91
Support 2 478.65
NSE INDIA Most Active Stocks
JPASSOCIAT 28.95 8.02%
SUZLON 19.10 1.06%
UNITECH 9.30 -1.06%
LITL 1.10 4.76%
KPIT 127.30 2.83%
JPPOWER 8.35 7.05%
GMRINFRA 19.15 1.86%
FEDERALBNK 115.00 -3.64%
ALOKTEXT 4.00 17.65%
GTLINFRA 7.60 18.75%
More..
NSE INDIA Top Gainers Stocks
VISESHINFO 0.15 50.00%
FCSSOFT 0.25 25.00%
GET&D 394.00 19.76%
IVRCLINFRA 6.50 19.27%
GTLINFRA 7.60 18.75%
HANUNG 5.15 18.39%
SUJANAUNI 1.30 18.18%
ALOKTEXT 4.00 17.65%
GUJNREDVR 2.65 15.22%
BHUSANSTL 74.80 14.11%
More..
NSE INDIA Top Losers Stocks
KSERASERA 0.10 -33.33%
NAKODA 0.30 -14.29%
XLENERGY 1.70 -8.11%
NFL 73.20 -6.99%
RENUKA 20.25 -6.90%
RESPONIND 61.80 -6.65%
LAKSHVILAS 183.35 -5.95%
RSYSTEMS 44.15 -5.76%
SGL 17.90 -5.29%
SGL 17.90 -5.29%
More..

IPCA Laboratories Limited (NSE: IPCALAB)

IPCALAB Technical Analysis 4
As on 26th Jul 2017 IPCALAB Share Price closed @ 493.85 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 550.12 & Sell for SHORT-TERM with Stoploss of 496.68 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPCALAB Target for July
1st Target up-side 539.21
2nd Target up-side 571.99
3rd Target up-side 604.76
1st Target down-side 445.69
2nd Target down-side 412.91
3rd Target down-side 380.14
IPCALAB Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 57.02 Sideways
MFI (14) MFI is 71.64 Sideways
CCI (20) CCI is Above 100 Over Bought
WILLIAM %R (14) William %R is Above -20 Over Bought
ADX (14) ADX is 14.07 Range Bound
PSAR Stoploss For Long Buy 436.10
10 Day Avg Volume Traded 10.85 % More then 10 Day Average Volume
IPCALAB Other Details
Segment EQ
Market Capital 34699423744.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipcalabs.com
IPCALAB Address
IPCALAB
142 AB, Kandivli Industrial Estate
Kandivli (West)
Mumbai, 400067
India
Phone: 91 22 6647 4747
Fax: 91 22 2868 6954
Interactive Technical Analysis Chart IPCA Laboratories Limited ( IPCALAB NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on IPCA Laboratories Limited
IPCALAB Business Profile
Ipca Labs is in the Pharmaceuticals - Bulk Drugs and Formulation sector. Ipca Laboratories (IPCA), a recognized trading house, exports to over 108 countries. Over 60% of its turnover comes from specialty formulations such as anti-malarials, anti-emetics, anti-hypertensives, antibiotics and other drugs. The balance comes from bulk drugs, drug intermediates, generic formulations, hospital products, ..etc. The company works out of its various divisions namely general pharma division, Intima division, Activa division, 3C division, Innova division and Hycare division. It is the largest Indian manufacturer of anti-malarial bulk drug chloroquine phosphate. The formulations manufacturing unit of the company in Athal, Silvassa is being expanded and upgraded to meet the growing formulations export business. The company exports formulations as well as APIs to several Asian countries. The company markets branded formulations to Sri Lanka, Myanmar and Vietnam. During 2004-2005, the company introduced 15 new products in the domestic market. New products introduced during the last three financial years now constitute nearly 24% of its domestic formulations sales. The company is setting up new formulations manufacturing unit at the special economic zone (SEZ) Indore. IPCA currently has five wholly-owned overseas subsidiary companies after amalgamation of the wholly-owned subsidiary Innotech Pharma with the company. The company plans to develop various APIs/intermediates having good potential for exports and local market. It plans additional investment in manpower, latest instrumentation to upgrade and strengthen R&D facilities. Also, the company aims at developing newer drug delivery systems along with developing formulations for developed market and bio-equivalence studies of the same. The current market capitalisation stands at Rs 8,614.35 crore.The company has reported a consolidated sales of Rs 1292.64 crore and a Net Profit of Rs 95.07 crore for the quarter ended Mar 2009. The company management includes Premchand Godha - Chairman & Managing Director, Ajit Kumar Jain - Joint Managing Director, Pranay Godha - Executive Director, Prashant Godha - Executive Director, Madhukar R Chandurkar - Director, Babulal Jain - Director, V V Subba Rao - Director, Anand T Kusre - Director, Dev Parkash Yadava - Director, Ramakanta Panda - Director. It is listed on the BSE with a BSE Code of 524494 and the NSE with an NSE Code of IPCALAB. Its Registered office is at 48, Kandivli Industrial Estate, Kandivli (West), Mumbai,Maharashtra - 400067.